These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 27506293)

  • 21. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loading of Extracellular Vesicles with Chemically Stabilized Hydrophobic siRNAs for the Treatment of Disease in the Central Nervous System.
    Haraszti RA; Coles A; Aronin N; Khvorova A; Didiot MC
    Bio Protoc; 2017 Jun; 7(20):. PubMed ID: 28868334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA.
    Stiles DK; Zhang Z; Ge P; Nelson B; Grondin R; Ai Y; Hardy P; Nelson PT; Guzaev AP; Butt MT; Charisse K; Kosovrasti V; Tchangov L; Meys M; Maier M; Nechev L; Manoharan M; Kaemmerer WF; Gwost D; Stewart GR; Gash DM; Sah DW
    Exp Neurol; 2012 Jan; 233(1):463-71. PubMed ID: 22119622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.
    Alvarez-Erviti L; Seow Y; Yin H; Betts C; Lakhal S; Wood MJ
    Nat Biotechnol; 2011 Apr; 29(4):341-5. PubMed ID: 21423189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. siRNA Loaded-Exosomes.
    Izco M; Alvarez-Erviti L
    Methods Mol Biol; 2021; 2282():395-401. PubMed ID: 33928586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
    Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
    Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
    Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
    Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain.
    Dar GH; Mendes CC; Kuan WL; Speciale AA; Conceição M; Görgens A; Uliyakina I; Lobo MJ; Lim WF; El Andaloussi S; Mäger I; Roberts TC; Barker RA; Goberdhan DCI; Wilson C; Wood MJA
    Nat Commun; 2021 Nov; 12(1):6666. PubMed ID: 34795295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs.
    Osborn MF; Alterman JF; Nikan M; Cao H; Didiot MC; Hassler MR; Coles AH; Khvorova A
    Nucleic Acids Res; 2015 Oct; 43(18):8664-72. PubMed ID: 26400165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington's disease gene expression following intranasal administration.
    Sava V; Fihurka O; Khvorova A; Sanchez-Ramos J
    Nanomedicine; 2020 Feb; 24():102119. PubMed ID: 31666200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
    Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
    Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Huntingtin associates with the actin cytoskeleton and α-actinin isoforms to influence stimulus dependent morphology changes.
    Tousley A; Iuliano M; Weisman E; Sapp E; Richardson H; Vodicka P; Alexander J; Aronin N; DiFiglia M; Kegel-Gleason KB
    PLoS One; 2019; 14(2):e0212337. PubMed ID: 30768638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin.
    Galvan L; Francelle L; Gaillard MC; de Longprez L; Carrillo-de Sauvage MA; Liot G; Cambon K; Stimmer L; Luccantoni S; Flament J; Valette J; de Chaldée M; Auregan G; Guillermier M; Joséphine C; Petit F; Jan C; Jarrige M; Dufour N; Bonvento G; Humbert S; Saudou F; Hantraye P; Merienne K; Bemelmans AP; Perrier AL; Déglon N; Brouillet E
    Brain; 2018 May; 141(5):1434-1454. PubMed ID: 29534157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNAi delivery by exosome-mimetic nanovesicles - Implications for targeting c-Myc in cancer.
    Lunavat TR; Jang SC; Nilsson L; Park HT; Repiska G; Lässer C; Nilsson JA; Gho YS; Lötvall J
    Biomaterials; 2016 Sep; 102():231-8. PubMed ID: 27344366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
    Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
    Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro evaluation of endothelial exosomes as carriers for small interfering ribonucleic acid delivery.
    Banizs AB; Huang T; Dryden K; Berr SS; Stone JR; Nakamoto RK; Shi W; He J
    Int J Nanomedicine; 2014; 9():4223-30. PubMed ID: 25214786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.
    Yang T; Fogarty B; LaForge B; Aziz S; Pham T; Lai L; Bai S
    AAPS J; 2017 Mar; 19(2):475-486. PubMed ID: 27882487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP.
    Hong Y; Zhao T; Li XJ; Li S
    J Neurosci; 2016 Aug; 36(34):8790-801. PubMed ID: 27559163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.